Exagen makes AVISE brand blood tests that help doctors diagnose autoimmune and related rheumatic diseases. XGN reports earnings on Tue, Nov 10, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 19 | Canaccord Genuity | Maintained | Buy | |
| Oct 13 | TD Cowen | Maintained | Buy | |
| Aug 5 | B. Riley Securities | Reiterated | Buy | |
| Jun 25 | Roth Capital | Initiated | Buy |
Seasonality
How XGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in XGN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XGN is in one of them and how their past XGN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered XGN in an article yet. Here's the latest on the wider market.
About Exagen
Exagen is a medical technology company based in Vista, California, that makes diagnostic tests for autoimmune and related rheumatic diseases. Its main product line, sold under the AVISE brand, includes AVISE CTD, which helps clinicians tell apart conditions with overlapping symptoms, such as lupus and rheumatoid arthritis. Its tests are used mainly by rheumatologists, with primary care physicians, other specialists, hospitals and healthcare systems also among its customers. The company runs its own clinical laboratory to process the tests.
- Headquarters
- Vista, CA
- Founded
- 2002
- Website
- exagen.com ↗